Moderna (MRNA) Revenue (2017 - 2026)

Moderna (MRNA) has 10 years of Revenue data on file, last reported at $389.0 million in Q1 2026.

• On a quarterly basis, Revenue rose 260.19% year-over-year to $389.0 million in Q1 2026; TTM through Mar 2026 was $2.2 billion, a 29.97% decrease from a year earlier, with the FY2025 full-year figure at $1.9 billion, down 39.93% from the prior year.
• Revenue for Q1 2026 stood at $389.0 million, down from $678.0 million in the prior quarter.
• Over the last five years, Revenue for MRNA reached as high as $6.1 billion in Q1 2022 and fell as low as $108.0 million in Q1 2025.
• Historically, Revenue has averaged $1.9 billion across 5 years, with a median of $1.0 billion in 2025.
• Across the five-year window, Revenue sank 92.76% in 2023 and soared 260.19% in 2026, its largest moves.
• Year by year, Revenue stood at $5.1 billion in 2022, then plunged by 44.71% to $2.8 billion in 2023, then sank by 65.64% to $966.0 million in 2024, then declined by 29.81% to $678.0 million in 2025, then slumped by 42.63% to $389.0 million in 2026.
• Per Business Quant data, the three most recent Revenue figures were $389.0 million in Q1 2026, $678.0 million in Q4 2025, and $1.0 billion in Q3 2025.